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1. Introduction 
Children represent a population at higher risk of Human Immunodeficiency Virus type 1 
(HIV-1) infection and AIDS-related death. Approximately 2.5 million (1.6–3.4) children are 
infected at present, accounting for 370,000 [230,000–510,000] new infections  and 260,000 
[150,000–360,000] deaths (Gray et al., 2001). About 90% of children living with HIV-1 are in 
sub-Saharan Africa. The paediatric HIV-1 epidemic is fuelled by HIV-1 infection in women 
of childbearing age. In fact, mother-to-child (perinatal) HIV-1 transmission during 
pregnancy, birth or breastfeeding accounts for the vast majority of HIV-1 cases in children. 
An estimated 2.4 million infected women give birth annually. This results in the birth of 
approximately 1,000 HIV-1–infected babies per day, of which 80% occur in resource-limited 
countries where there are no effective programs for prevention of mother-to-child 
transmission (MTCT) of HIV-1 . Almost two decades ago, the introduction of antiretroviral 
chemoprophylaxis to prevent MTCT of HIV-1 was an important milestone in paediatric 
HIV-1. The use of antiretroviral drugs and elective caesarean section have reduced the 
incidence of MTCT in industrialised countries to <2% since 1997 (The European 
Collaborative Study [ECS], 2005; Connor et al., 1994). However, such interventions to 
prevent MTCT of HIV-1 are still not widely accessible or available in most resource-limited 
countries where the rate of transmission is estimated at 12–40% (De Cock et al., 2000). 
Concerning the diagnosis and treatment of HIV-1, significant improvements have been 
made over the last few years, yet much more needs to be done. The first evidence of the 
efficacy of antiretroviral therapy (ART) in HIV-1–infected children was published 20 years 
ago (Pizzo et al., 1988). Since then, the introduction of highly active antiretroviral therapy 
(HAART) into medical care for HIV-1–infected children and adolescents has increased life 
expectancy and resulted in AIDS incidence decline in both industrialised countries and 
resource-limited settings (Judd et al., 2007; Patel et al., 2008; Puthanakit et al., 2007; Reddi et 
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al., 2007). Some studies have also described the immunovirological impact of HAART (Fraaij 
et al., 2005; Scherpbier et al., 2006; Walker et al., 2004). Nevertheless, in developing countries 
early diagnosis is a major challenge and ART is often started late. The clinical impact of 
early treatment has been recognised (Faye et al., 2004; Violari et al., 2007); in fact, in the 
absence of treatment, 50% of infants die before their second birthday (Newell et al., 2004). 
Moreover, lack of resources restricts drug supply. Despite the number of children receiving 
ART increased from about 75,000 in 2005 to 360,000 in 2009, these represent en estimated 
ART coverage of 28% [21-43%] of all children less than 15 years who need ART in resource-
limited settings (WHO, 2010). On the contrary, in industrialised countries antiretroviral 
drugs are widely available. In addition, new therapeutic options have been developed for 
the paediatric population in recent years, such as the protease inhibitor darunavir approved 
for children aged ≥ 6 years and adolescents (Blanche et al., 2009), or are under evaluation in 
ongoing clinical trials, including the second generation non-nucleoside reverse transcriptase 
inhibitor etravirine (ClinicalTrials.gov 2008b, 2009a), the new protease inhibitor tipranavir 
(Salazar et al., 2008), and the new families of antiretrovirals, such as the CCR5 antagonists 
and integrase inhibitors (ClinicalTrials.gov 2007, 2008a, 2009b). 
2. Impact of antiretroviral therapy 
Given that HIV-1 infection has turned into a chronic condition and that exposure to 
antiretrovirals is likely to be life-long, continuous assessment of the impact of HAART on 
progression of perinatal HIV-1 infection remains an important public health issue to improve 
health care strategies. Here, we report the evaluation of HAART effectiveness on the incidence 
of AIDS and death, and the trends in the underlying causes of death at population level over 
almost three decades in Madrid (Spain). In Western Europe, Spain continues to be one of the 
countries with the highest AIDS incidence rate and prevalence. Within Spain, the Comunidad 
Autónoma de Madrid is the area most affected by the infection, with a total of 18,866 AIDS cases 
up to 2010 (24% of the national cases) (Centro Nacional de Epidemiología [CNE], 2010). The 
high HIV-1 prevalence had a direct impact on the spread of the infection within the infant 
population and although the risk of perinatal transmission of HIV-1 has decreased below 2% 
in recent years, paediatric HIV-1 cases are still being diagnosed (Palladino et al., 2008). In the 
Comunidad Autónoma de Madrid, a total of 237 cumulative AIDS cases due to vertical 
transmission were reported to the National AIDS Registry from 1981 to 2010 (CNE, 2010). The 
introduction of HAART in late 1996 and its universal and free availability (Ministerio de 
sanidad y Consumo, 1998) offered the opportunity to control HIV-1 disease progression in the 
paediatric population (2005; Resino et al., 2006b). The aim of this study was to describe the 
mortality and AIDS rates and changes in underlying causes of death in HIV-1–infected 
paediatric patients. Moreover, risk factors associated with shorter first-line HAART duration 
among antiretroviral-naïve patients who began HAART after 1996 were examined.  
2.1 Study population and methods 
The HIV Paediatric Cohort of the Comunidad Autónoma de Madrid was established in 1995 as an 
open cohort of paediatric patients infected by HIV-1 through MTCT, for whom it was assumed 
that HIV-1 transmission occurred on the date of birth (de Martino et al., 2000). The cohort has 
included all HIV-1–infected patients identified in a multicenter network of nine referral 
paediatric hospitals from January 1982 (birth date of the first MTCT–infected child in Madrid). 
Children infected before 1995 were enrolled retrospectively, while those infected after 1995 
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were enrolled prospectively. Complete ascertainment of all records was carefully sought. 
Informed consent was obtained from mothers of all patients. The Institutional Ethics 
Committee approved the study. HIV-1 testing during pregnancy was offered to all women 
until 1998, when routine testing was introduced for all pregnant women. Patients were 
actively followed up every 3–6 months (Centers for Disease Control and Prevention [CDC] 
1998). At the beginning of the study, the diagnosis of HIV-1 infection was based on the results 
of a serologic test for HIV-1 antibody, which was performed routinely for children born to 
seropositive women. When the result of the serologic test was positive, the infection was 
confirmed by paediatricians and/or through hospital summaries. Later, the diagnosis was 
done by positive results of HIV-1 PCR DNA and peripheral blood mononuclear cells viral 
culture assays on two separate samples (Resino et al., 2006a). The clinical classification and 
definition of AIDS-related events were based on international guidelines (CDC 1994). Children 
in the A or B clinical category who became older than 13 years were not categorised as having 
AIDS by CD4+ cell count criteria when they had <200 cells/ml (CDC 1992). 
Deaths were reported by paediatricians. The underlying cause of death (the disease/injury 
which initiated the morbid event leading to death) was confirmed by reviewing medical 
histories or autopsy certificates and interviewing paediatricians. Patients were cross-checked 
with the National Death Index to validate their causes of death classified as: “AIDS-defining” 
when attributable to a disease in the C clinical category (CDC 1992, 1994); “HIV-related” when 
attributable to a category A or B disease (CDC 1992, 1994) or to ARV adverse events; “non-
HIV-related”: all other causes. To report the underlying cause of death, when multiple 
concurrent causes contributed to death, patients were included as many times as the number 
of illnesses diagnosed. The study period comprised a pre-HAART era (1982-1996) and a post-
HAART era (1997-2009), and was divided into six calendar periods (CP) on the basis of the 
changing HIV-1 therapy management. CP1 (1982-1989): it was chose as the reference period, 
when ART was not routinely available; CP2 (1990–1993): the standard of care was zidovudine 
monotherapy; CP3 (1994–1996): children were receiving dual-nucleoside regimen; CP4 (1997–
1998): when HAART, a combination of three or more drugs, was introduced; CP5 (1999–2004): 
early-HAART period; CP6 (2005–2009): late-HAART period. Information on socio-
demographic characteristics, mother’s transmission category, clinical and immunovirological 
data and the antiretroviral therapy were recorded. Any change in two or more antiretroviral 
drugs that lasted ≥14 days, excluding dosage changes, in the presence of detectable HIV-1 
RNA, was considered to indicate the start of a new regimen. 
2.1.1 Statistical analysis 
AIDS and mortality rates were calculated as the number of new AIDS and death cases per 
hundred person-years (p-y) of follow-up. Individuals were followed from the date of 
enrolment (i.e., date of HIV-1 diagnosis or first blood test) until the date of development of 
the event of interest (AIDS or death) or December 31, 2009 (administrative censoring date), 
whichever occurred first. The risk of progression to AIDS and death over time was 
estimated by survival analyses using Kaplan-Meier curves and Cox proportional hazards 
models. Time was calculated from the birth date so that comparisons across different 
calendar periods were based on individuals who were infected for the same length of time. 
All models were stratified by hospital and adjusted for potential confounders (gender, 
mother’s transmission category and immunological category). Fisher exact test, χ2 or Mann-
Whitney U test were used to derive P-values. Poisson regression was used to compare 
mortality and infection rates between our cohort and the age-similar general population 
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living in the Comunidad Autónoma de Madrid. The median duration of initial HAART regimen 
was determined by Kaplan-Meier analysis. Univariate proportional hazards regressions 
were used to identify factors associated with a shorter initial regimen. The variables 
examined included demographics, socio-economic characteristics, baseline laboratory values 
(CD4+ cell count, HIV-1 RNA, haemoglobin), clinical status and adherence to initial HAART 
regimen. Then, multivariate regression analysis was performed including all factors for 
which the results of univariate analysis were statistically significant (P<0.05, 2-sided). 
Analyses were performed with SPSS 16 and Epidat 3.1. 
3. Results 
Overall, 484 children who acquired HIV-1 from their mothers between 1982 and 2009 
were enrolled and followed for 5298.2 person-years (11.6 years; interquartile range (IQR): 
5.2-16.7). HIV-1 infection occurred mainly in 1992 [IQR: 1988-1995]; 270 (56%) patients 
were girls and 299 (62%) had a mother who acquired the virus through injection drug 
use. Table 1 provides the characteristics of the children at the end of each calendar 
period (CP). The cohort had the highest number of enrolled children between 1994 and 
1996; in the last period (2005-2009) there were 279 children included, of whom 13 were 
born in this period. The sex ratio remained stable over time (CP1: 1.0; CP6: 1.4), while the 
median age (CP1: 2.6 [1.0-4.4]; CP6: 14.8 [11.6-17.5]; P<0.001) and the proportion of 
immigrants (CP1: 3.1; CP6: 15.5; P<0.0001) increased. An increase of the median CD4+ 
cell percentage at the end of each calendar period was observed (CP2: 22.5 [11.9-32.1]; 
CP4: 26.5 [18.2-33.7]; CP6: 33.4 [28.0-39.7]) and a concomitant decrease of HIV-1 RNA 
since 1997 (median log10 copies/ml CP4: 4.31 [3.80-4.91]; CP6: 2.60 [1.70-3.55]). The 
proportion of children with <400 copies/ml was 9% (13/151) in CP3, 20% (39/196) in 
CP4, 60% (150/248) in CP5, and 80% (160/199) in CP6. Two adolescents died in CP2 
achieving undetectable HIV-1 RNA at death. The CD8+ cell percentage remained stable 
(CP2: 42.0 [29.0-52.0]; CP4: 43.7 [35.6-52.5]; CP6: 38.9 [31.7-45.7]). The changes over time 
in antiretroviral therapy management are described in Fig. 1. Monotherapy was used in 
the early 1990s and dual-nucleoside therapy in mid-1990s. An increasing proportion of 
children receiving HAART from 1997 onward was observed; by 2005, up to 80% of the 
children were on HAART. 
3.1 Time to AIDS or death 
Information on 471 children, of whom 285 (61%) developed an AIDS-defining disease, was 
available for the progression to AIDS analyses. The AIDS incidence rate increased over time 
until 1989 (32.6 per 100 p-y), it arose again during the first half of the 1990s (13.2 in 1991; 18.8 
in 1995) and waned off thereafter (3.2 in 1999; 0.0 in 2009) (Fig. 2). The cumulative incidence 
curves showed a reduction in the proportion of patients developing AIDS after 1997 
compared to the period 1982-1989 (Fig. 3A). Multivariate Cox analysis showed a more 
pronounced decline in the last period (CP6) (AHR: 0.07; 95%CI: 0.04-0.16) than in the CP5 
(AHR: 0.23; 95%CI: 0.15-0.37) (Table 2). A total of 159/484 (33%) deaths occurred. The death 
incidence rate was 7.4 per 100 p-y at risk in 1986, it peaked in 1995 (10.1 per 100 p-y) and 
declined thereafter (0.7 in 1999; 0.0 in 2009) (Fig. 2). The incidence of death decreased since 
1997 compared to the period 1982-1989 (Fig. 3B, Table 2). Multivariate analysis showed more 
marked improvements in survival in the CP6 (AHR: 0.16; 95%CI: 0.05-0.50) than in the CP5 
(AHR: 0.25; 95%CI: 0.11-0.56). 
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 Period 
Characteristics 
CP1 
(80-89) 
CP2 
(90-93)
CP3 
(94-96)
CP4 
(97-98)
CP5 
(99-04) 
 
CP6 
(05-09) 
N. of HIV-1–infected patients 168 280 317 282 315  279 
Age, years (median, IQR) 
2.6 
(1.0 – 4.4)
4.0 
(1.8 – 6.6)
5.0 
(2.6 – 8.0)
6.7 
(3.8 – 9.6)
11.1 
(7.8 – 14.0) 
 
14.8 
(11.6–17.5) 
        
Date of birth, n. of patients        
1980-1989 168 144 115 85 79  47 
1990-1993 – 136 115 93 90  85 
1994-1996 – – 87 73 68  63 
1997-1998 – – – 31 29  27 
1999-2004 – – – – 49  44 
2005-2009 – – – – –  13 
        
Sex ratio, n. of girls 1.00 1.19 1.23 1.27 1.32  1.41 
        
Geographic origin, n. (%)        
Spain 
156 
(92.9) 
264 
(94.3) 
298 
(94.0) 
256 
(90.8) 
271 
(86.0) 
 
235 
(84.0) 
Central America 0 (0) 3 (1.1) 4 (1.3) 8 (2.8) 10 (3.2)  9 (3.2) 
South America 3 (1.8) 4 (1.4) 6 (1.9) 6 (2.1) 8 (2.5)  8 (2.9) 
North Africa 0 (0) 0 (0) 1 (0.3) 1 (0.4) 1 (0.3)  2 (0.7) 
Sub-Sahara Africa 0 (0) 3 (1.1) 5 (1.6) 8 (2.8) 19 (6.0)  20 (7.2) 
Other 2 (1.2) 2 (0.7) 2 (0.6) 3 (1.1) 5 (1.6)  4 (1.4) 
Unknown/Unavailable 7 (4.2) 4 (1.4) 1 (0.3) - 1 (0.3)  1 (0.4) 
        
Maternal transmission, n. (%)        
Injecting drug use 
119 
(70.8) 
189 
(67.5) 
196 
(61.8) 
168 
(59.6) 
185 
(58.7) 
 
154 
(55.2) 
Heterosexual 29 (17.3) 56 (20.0) 69 (21.8) 69 (24.5) 78 (24.8)  74 (26.5) 
IDU / Heterosexual 13 (7.7) 23 (8.2) 29 (9.1) 24 (8.5) 23 (7.3)  19 (6.8) 
Transfusion 3 (1.8) 3 (1.1) 7 (2.2) 6 (2.1) 6 (1.9)  6 (2.2) 
Unknown/Unavailable 4 (2.4) 9 (3.2) 16 (5.0) 15 (5.3) 23 (7.3)  26 (9.3) 
        
Clinical category C, n. (%) 69 (41.3) 106 (38.3) 137 (44.1) 102 (37.4) 124 (40.8)  102 (37.5) 
        
Death, n. (%) 21 (12.5) 49 (17.5) 63 (19.9) 12 (4.3) 10 (3.2)  4 (1.4) 
Table 1. Demographic and clinical characteristics of the HIV-1–infected patients enrolled in 
the HIV Paediatric Cohort of the Comunidad Autónoma de Madrid at the end of each calendar 
period (CP). IQR: interquartile range; clinical classification was based on the 1994 revised 
CDC guidelines. IDU: injecting drug use. 
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Fig. 1. Use of antiretroviral therapy among HIV-1 vertically infected children enrolled in the 
HIV Paediatric Cohort of the Comunidad Autónoma de Madrid. NT: not treated; MT: 
monotherapy; combined/dual-nucleoside therapy; HAART: highly active antiretroviral 
therapy. 
 
  AIDS 
Calendar period  N. N. of cases Adjusted HR 
(95% CI) 
1982 – 1989 
1990 – 1993 
1994 – 1996 
1997 – 1998 
1999 – 2004 
2005 – 2009 
 
167 
232 
255 
199 
216 
178 
69 
61 
81 
28 
37 
9 
1.00 
0.49 (0.33 - 0.69) 
0.64 (0.44 - 0.91) 
0.39 (0.25 - 0.63) 
0.23 (0.15 - 0.37) 
0.07 (0.04 - 0.16) 
  Death 
Calendar period  N. N. of cases Adjusted HR 
(95% CI) 
1982 – 1989 
1990 – 1993 
1994 – 1996 
1997 – 1998 
1999 – 2004 
2005 – 2009 
 
168 
280 
317 
282 
315 
279 
21 
49 
63 
12 
10 
4 
1.00 
1.33 (0.77 - 2.28) 
1.71 (1.00 – 2.94) 
0.54 (0.25 - 1.14) 
0.25 (0.11 - 0.56) 
0.16 (0.05 - 0.50) 
Table 2. Effect of calendar period on the risk of AIDS and death. Note: Adjusted hazard 
ratios were derived from a standard Cox proportional hazard model that included calendar 
period (external time-dependent covariate), gender, mother’s transmission category, 
immunological category and it is stratified by hospital. 
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  AIDS Death
Years  p-y N. Rate p-y N. Rate 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
1994 
1995 
1996 
1997 
1998 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
2007 
2008 
2009 
 
2
10 
24 
44 
65 
79 
89 
98 
103 
121 
147 
158 
173 
170 
164 
156 
158 
155 
155 
155 
155 
152 
151 
150 
142 
136 
132 
128
0
0 
0 
2 
8 
7 
20 
32 
9 
16 
16 
20 
21 
32 
28 
18 
10 
5 
10 
4 
10 
4 
4 
2 
5 
2 
0 
0
0,0 
0,0 
0,0 
4,6 
12,4 
8,9 
22,6 
32,6 
8,7 
13,2 
10,9 
12,7 
12,2 
18,8 
17,1 
11,5 
6,3 
3,2 
6,5 
2,6 
6,5 
2,6 
2,6 
1,3 
3,5 
1,5 
0,0 
0,0 
 
2
10 
24 
45 
68 
84 
105 
133 
154 
177 
206 
221 
239 
248 
248 
256 
263 
269 
275 
278 
283 
276 
271 
263 
244 
233 
217 
209
0
0 
0 
0 
5 
3 
2 
11 
8 
11 
17 
13 
20 
25 
18 
7 
5 
2 
1 
2 
1 
3 
1 
1 
1 
1 
1 
0
0,0 
0,0 
0,0 
0,0 
7,4 
3,6 
1,9 
8,3 
5,2 
6,2 
8,3 
5,9 
8,4 
10,1 
7,3 
2,7 
1,9 
0,7 
0,4 
0,7 
0,4 
1,1 
0,4 
0,4 
0,4 
0,4 
0,5 
0,0 
Fig. 2. Annual AIDS and mortality incidence rates per 100 person-years (p-y) in the HIV 
Paediatric Cohort of the Comunidad Autónoma de Madrid. 
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In the population aged 0-19 years of the Comunidad Autónoma de Madrid, the mortality 
decreased from 4.2 deaths per 10,000 inhabitants in 1996 to 3.5 in 2007. In spite of the mortality 
decline in our cohort, it still was 10.4-fold (95%CI: 5.8-18.8; P<0.001) higher than in age-similar 
general population after 1999. Since 1999, the HIV-1–infected infants had a higher mortality 
rate than children/adolescents (IRR: 6.9; 95%CI: 2.3-20.3; P<0.001), as in the general population 
(IRR: 18.9; 95%CI: 17.9-19.9; P<0.001). A lower decrease of mortality among HIV-1–infected 
infants (IRR: 2.6; 95%CI: 0.9-7.4; P=0.069) between pre-HAART and post-HAART era than 
among older patients (IRR: 12.5; 95%CI: 7.6-20.4; P<0.001) was observed. On the contrary, 
mortality decreased equally in infants (IRR: 1.8; 95%CI: 1.8-1.9; P<0.001) and 
children/adolescents (IRR: 1.5; 95%CI: 1.5-1.6; P<0.001) in the general population. 
3.2 Causes of death 
Overall, 169 causes of death were documented for 151/159 (95%) patients (Table3). The 81% 
(137/169) were AIDS-defining, 12% (20/169) HIV-related and 7% (12/169) non-HIV-related. 
Multiple causes of death were reported in 16/151 (11%) patients, 3.2 (0.6–6.3) years old at 
death, of which 7 were infants: 13/129 (10%) died in pre-HAART era and 3/22 (14%) in 
post-HAART era. Concomitant pathologies were diagnosed in 101/151 (67%) patients 
(Table 4). The majority (83%) of the subjects died in the post-HAART era had a 
low/medium socio-economic status. From 1999 to 2007, the risk of death from infections 
was 115.9 times (95% CI: 42.0–265.8; P<0.001) higher in our cohort than in the Comunidad 
Autónoma de Madrid. It was not possible to evaluate the risk of death from other causes than 
infections due to the low number of events. 
AIDS-defining causes were 82% (118/144) in pre-HAART and 76% (19/25) in post-HAART 
era. The most frequent contributing events were opportunistic infections (58%, 79/137) 
(Table 4), wasting syndrome (19%, 26/137) and lymphoid interstitial pneumonia (12%, 
16/137). The largest components of opportunistic infections were bacterial (20%, 28/137), 
fungal (mainly Pneumocystis jiroveci; 15%, 20/137), and mycobacterial infections (mainly 
Mycobacterium tuberculosis; 10%, 14/137). These three etiologic pathogens were associated 
with the only cases of death occurred in 2005-2007. No statistically significant changes over 
time were observed in the proportions of the causes of death. HIV-related causes were 11% 
(16/144) in pre-HAART and 16% (4/25) in post-HAART era. Overall, the leading causes of 
death were infections (75%, 15/20), mainly bacterial (65%, 13/20), and bleeding (15%, 3/20). 
The causes of death reported in post-HAART era were: bacterial infection, pulmonary 
bleeding caused by thrombocytopenia, pulmonary arterial hypertension and lactic acidosis 
(1 case each). Non-HIV-related causes were 7% (10/144) in pre-HAART and 8% (2/25) in 
post-HAART era. Infections were the main cause of death (75%, 9/12), mainly viral 
infections (67%, 8/12), followed by cancer (17%, 2/12) and hepatic pathology (8%, 1/12). 
The only causes of death reported in post-HAART era were cancer and hepatic failure (1 
case each). 
3.3 Duration of HAART regimen 
Of 484 patients included in the HIV Paediatric Cohort of the Comunidad Autónoma de 
Madrid, 105 (22%) were naïve to antiretrovirals when HAART began as of January 1997. It 
was possible to analyse the duration of the first HAART regimen in 82 of them. Half of the 
patients were girls (42; 51%) and had a median age at HAART initiation of 3.6 years (0.6-
7.3).  
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Fig. 3. Kaplan-Meier curves for HIV-1–infected children enrolled in the HIV Paediatric 
Cohort of the Comunidad Autónoma de Madrid without AIDS (A) and for survival (B) in 
different calendar periods. 
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Pre-HAART (1982-
1996) 
 
Post-HAART 
(1997-2009) 
Cause of death  N=144 (85.2%)  N=25 (14.8%) 
Cancer  6 (4.2)  3 (12.0) 
NHL  5 (3.5)  2 (8.0) 
HL  1 (0.7)  -- 
Others  --  1 (4.0) 
Infections  90 (62.5)  13 (52.0) 
Bacterial infections  34 (23.6)  7 (28.0) 
Pneumonia  20 (13.9)  3 (12.0) 
Sepsis  14 (9.7)  3 (12.0) 
Meningitis  --  1 (4.0) 
Fungal infections  17 (11.8)  3 (12.0) 
Pneumonia  13 (9.0)  3 (12.0) 
Esophageal  4 (2.8)  -- 
Mycobacterial infections  13 (9.0)  3 (12.0) 
Nontuberculous  8 (5.6)  2 (8.0) 
Tuberculosis  5 (3.5)  1 (4.0) 
Viral infections  15 (10.4)  -- 
Pneumonia  5 (3.5)   
Sepsis  6 (4.2)   
AGE  3 (2.1)   
PML  1 (0.7)   
Parasitic infections  11 (7.6)  -- 
Cryptosporidiasis  9 (6.3)   
Toxoplasmosis  1 (0.7)   
Leishmaniasis  1 (0.7)   
Other causes  48 (33.3)  9 (36.0) 
Wasting  22 (15.3)  4 (16.0) 
Pulmonary  15 (10.4)  2 (8.0) 
Encephalopathy  9 (6.3)  -- 
Hepatic  --  1 (4.0) 
Bleeding  2 (1.4)  1 (4.0) 
Lactic acidosis  --  1 (4.0) 
Table 3. All causes of death for HIV-1–infected children enrolled in the HIV Paediatric 
Cohort of the Comunidad Autónoma de Madrid stratified by pre-HAART era and post-HAART 
era. Pulmonary cause of death includes lymphoid interstitial pneumonia cases and 1 case of 
pulmonary hypertension. AGE: acute gastroenteritis; HL: Hodgkin’s lymphoma; NHL: non-
Hodgkin’s lymphoma; PML: progressive multifocal leukoencephalopathy (JC virus). 
Percentage may not total 100 because of rounding. 
www.intechopen.com
 HAART and Causes of Death in Perinatally HIV-1-Infected Children  
 
651 
  
Pre-HAART (1982-
1996) 
 
Post-HAART (1997-
2009) 
Opportunistic infection  N=67/129 (51.9%)  N=12/22 (54.5%) 
Recurrent bacterial infection  22 (32.8)  6 (50.0) 
Pneumocystis jiroveci  13 (19.4)  3 (25.0) 
Cryptosporidiosis  9 (13.4)  0 
Nontuberculous 
mycobacteria 
 6 (9.0)  2 (16.7) 
Mycobacterium tuberculosis  5 (7.5)  1 (8.3) 
Candidasis  4 (6.0)  0 
Cytomegalovirus  6 (9.0)  0 
Toxoplasmosis  1 (1.5)  0 
JC virus  1 (1.5)  0 
Comorbidity*  N= 87/129 (64.9%)  N=14/22 (60.9%) 
Wasting  52 (38.8)  11 (47.8) 
Encephalopathy  50 (37.3)  7 (30.4) 
Hepatic  17 (12.7)  2 (8.7) 
Miocardiophaty  20 (14.9)  2 (8.7) 
Hematologic alterations  15 (11.2)  3 (13.0) 
Candidiasis  10 (7.5)  -- 
Hypertension  3 (2.2)  -- 
Nephropathology  3 (2.2)  -- 
Giardiasis  1 (0.7)  -- 
HSV  1 (0.7)  -- 
Table 4. Prevalence of opportunistic infections and comorbidity in the deceased patients of 
the HIV Paediatric Cohort of the Comunidad Autónoma de Madrid, stratified by pre-HAART 
and post-HAART era. HSV: Herpes simplex virus. *Note: Patients can be counted more than 
once. 
The majority originated from Spain (58; 71%) and 19 (23%) were adopted or lived in 
institutions. The socio-economic status was medium-high for 28 (56%) out of 50 patients and 
low for 22 (44%). At baseline, the median CD4+ cell count was 707 (19%) cells/ml (212-1,443) 
and HIV-1 RNA was 100,000 (5.0 log10) copies/ml. The median duration of the first HAART 
regimen was 40.5 months (20.9-80.2). Fifty (61%) subjects were still on the same regimen at 
the end of the follow-up (Fig. 4, circle chart), being the median HAART duration in this 
group of 64.5 months (28.6-95.1). The rest of the study group (32/82; 39%) switched to a 
second regimen after 25.9 months (12.4-39.2) of first regimen. The median first-line HAART 
duration was significantly different between the two groups (P<0.0001). Among the 32 
patients who experienced first-line HAART discontinuation, up to 6 switches to successive 
regimens were observed and had a median duration of 25.9 months (20.7-29.2) (Fig. 4, bar 
chart). The cumulative incidence curves for time to initial HAART regimen discontinuation 
showed a longer median HAART duration for the 65/82 (79%) children who started the 
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therapy after 6 months of age compared with the 17 (21%) infants who started at or before 6 
months (P=0.033) (Fig 5A). In addition, this analysis showed a longer median HAART 
duration for the 31 (60%) out of 52 subjects with good/perfect adherence compared with the 
21 (40%) subjects with poor/intermediate adherence (P<0.0001) (Fig. 5B). Initial HAART 
regimen discontinuation remained associated to younger ages (AHR: 4.56; 95%CI: 1.76–
11.86; P=0.002) and poor adherence (AHR: 5.02; 95%CI: 2.02–12.47; P=0.001) in the 
multivariate analysis performed for 52 patients (Table 5). The most frequently prescribed 
first-line regimen was based on protease inhibitors, while one-quarter of the patients 
received therapy based on non-nucleoside reverse-transcriptase inhibitors (Fig. 6). Two 
nucleosides backbone therapy remains the cornerstone for all patients but one who had 3 
nucleosides. For patients who discontinued the first-regimen, there was a difference, 
approaching statistical significance, between the duration of the PI-based therapy (30.0 
months [13.1-40.5]) and the NNRTI-based therapy (15.2 [5.5-23.2]; P=0.054). 
 
 
Fig. 4. Relative proportion of patients according to the number of HAART regimens among 
the 82 antiretroviral-naïve patients who start HAART since 1997 (circle chart); months of 
HAART regimen duration among the 32 patients with regimen switch (bat chart). 
 
>6 months old≤ 6 months old
Good/perfect
Poor/intermediate 
 
(A)     (B) 
Fig. 5. Kaplan-Meier curves for time to discontinuation of first HAART regimen according 
to the age of HAART initiation (A) and to adherence to first HAART regimen (B). 
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  First HAART regimen discontinuation 
  N. N. of 
cases (%)
Adjusted HR 
(95% CI) 
Age at HAART initiation 
> 6 months 
≤ 6 months 
 
Adherence to first HAART regimen 
Good/perfect 
Poor/intermediate 
 
 
40 
12 
 
 
31 
21 
 
14 (35.0) 
8 (66.7) 
 
 
8 (25.8) 
14 (66.7) 
 
1.00 
4.56 (1.76 – 11.86) 
 
 
1.00 
5.02 (2.02 – 12.47) 
Table 5. Effect of age at HAART initiation and adherence on the risk of first HAART 
regimen discontinuation. Note: Adjusted hazard ratios were derived from a standard Cox 
proportional hazard model. 
 
 
Fig. 6. Relative proportion of initial HAART regimen types among the 82 antiretroviral-
naïve patients who started HAART since 1997 (circle chart); months of HAART regimen 
duration in patients who did not suspended the first HAART regimen (dark coloured bars) 
and who suspended the first regimen (light coloured bars). NRTI: nucleoside reverse-
transcriptase inhibitor; NNRTI: non-nucleoside reverse-transcriptase inhibitor; PI: protease 
inhibitor. 
4. Discussion 
The results of this multicenter study on 484 patients infected by HIV-1 through perinatal 
transmission from the region of Madrid, show that the immunovirological response observed 
after the introduction of HAART has improved steadily since 1997. Also, an increase in clinical 
outcome with calendar period was observed. The marked reduction in progression to AIDS 
and death (by 93% and 84%, respectively) in recent years compared to 1982-1989 suggests a 
relationship between clinical outcome and HAART, which became widely available from 1997 
onward. However, in the latter period, a low but stable mortality rate was recorded, in 
accordance with those recently reported by others (Brady et al., 2010; Judd et al., 2007).  
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Remarkably, mortality continued to be more than ten-fold higher in our cohort than in age-
similar general population after 1996 and mainly affected patients of low/medium socio-
economic status (Palladino et al., 2008).  In addition, HIV-1–infected infants were still at 
higher risk for death compared with older paediatric patients, being this pattern mirrored in 
the general paediatric population and maybe attributable to the immature of the immune 
system (Gortmaker et al., 2001). Finally, the mortality trend had a strikingly lower decrease 
among infants than among children aged ≥ 1 year in our cohort, where it decreased equally 
in both groups in the general population. These findings highlight the HIV-1-infected 
infants as a major target for healthcare policy. We observed very high AIDS and mortality 
incidence rates during the first years of follow-up. These data on mortality are consistent 
with historical European series (ECS, (1994). and with data on HIV-1 progression in children 
living in setting where they do not receive medical care (Brahmbhatt et al., 2006; Marinda et 
al., 2007). In fact, zidovudine monotherapy administration to paediatric patients started only 
in 1988 (Pizzo et al., 1988) and in our cohort the majority of the children were still untreated 
in this year. Moreover, the high HIV-1 prevalence among the female population fuelled by 
the so called “epidemic of heroin” had a direct impact on the spread of the infection in 
infants. 
Our study shows that monotherapy exerted some benefit in the management of 
symptomatic children (Butler et al., 1991; McKinney et al., 1991; Resino et al., 2006b). 
Nevertheless, it had a time-limited effect due to ongoing viral replication that inevitably 
leads to the emergence of resistant HIV-1 quasispecies, which was also promoted by the 
lack of drug dosage adjustments for children at that time. The dual-nucleoside therapy 
proved to be more effective than monotherapy (Englund et al., 1997; Resino et al., 2006b). 
However, in our setting its effect on mortality or AIDS prevention between 1994- 1996 
was similar to that exerted by monotherapy. This finding might be partially attributable to 
the regimen switch to dual-drug therapy (mainly zidovudine plus didanosine) after 
several years of zidovudine treatment in many children, when zidovudine was not more 
completely active. Thus, even with perfect adherence, dual-drug therapy was only 
partially suppressive being administered as functional monotherapy and due to cross-
resistance within the nucleoside analogue class. In addition, during this period more than 
40% of the children were still untreated and more than 35% were on monotherapy. 
Previous studies reported the effectiveness of HAART on the risk of death in the setting of 
large paediatric cohorts, but these had limited follow-up and lacked assessment of the 
progression to AIDS (de Martino et al., 2000; Gortmaker et al., 2001). In 2000, the Italian 
Register for HIV Infection in Children (de Martino et al., 2000) observed a reduction in the 
mortality rate of 71% in individuals undergoing triple-combination therapy compared 
with untreated patients, while Gortmaker and colleagues found a 67% reduction 
comparing HAART with other therapy (Gortmaker et al., 2001). Important reductions of 
76% have also been reported recently by a 10-year follow-up survey (Patel et al., 2008). 
Our analyses found a stronger reduction (84%), but it is not directly comparable with 
previous published data due to the longer follow-up and to the difference in the 
performed analyses. In fact, we dealt with the trend of the risk of death in different 
calendar periods considered as an external time-dependent covariate. The high prevalence 
of comorbidities, along with multiple causes of death, resulted in increasing complexity of 
the management of patients with HIV/AIDS. 
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In terms of specific causes of death, AIDS–defining events were the most represented, with 
proportions higher than that recently observed in adults (Martinez et al., 2007; Palella et al., 
2006). This finding might be directly linked to a late HIV-1 diagnosis at the beginning of the 
epidemic and to the persistence of opportunistic infections, that were the leading AIDS–
defining causes of death (Brady et al., 2010; Selik & Lindegren 2003), although less 
represented since HAART advent (Currier et al., 1998; Kaplan et al., 2001). As in previous 
studies, bacterial infections were the largest component of opportunistic infections (Gona et 
al., 2006; Langston et al., 2001). Although specific information for their aetiology was mainly 
unavailable, we supposed that pneumococcus (Streptococcus pneumoniae) might has been the 
prominent microbial on the basis of recent reports (Cotton et al., 2008; Gortmaker et al., 
2001; Kapogiannis et al., 2008). In addition, the pneumococcal conjugate vaccine available 
since 2000 (Black et al., 2000) and recommended for all HIV-infected children, has a lower 
efficacy in these patients than in HIV-uninfected children (Bliss et al., 2008). Some bacterial 
infections occurred with normal CD4+ cell percentage (≥25%), consistently with previous 
report (Gona et al., 2006), maybe because the HIV-1 infection does not allow the correct 
development of primary immune function leading to the production of polyclonal, non-
specific immunoglobulin increasing the risk of infections with encapsulated bacteria (Brady 
et al., 2010; Cotton et al., 2008; Gortmaker et al., 2001; Kapogiannis et al., 2008). The 
population-based analysis yielded consistent results with studies of HIV–infected patients 
(Kapogiannis et al., 2008; Martinez et al., 2007), highlighting a higher incidence of infections 
in our cohort than in the general population of similar age from the same region. Along with 
host immune factors (Janoff et al., 1992), antimicrobial resistance (Cotton et al., 2008; Jaspan 
et al., 2008), comorbidity and co-infections might have contributed to the high risk of death 
from opportunistic infections. The introduction of both Pneumocystis pneumonia 
prophylaxis (CDC 1995; Simonds et al., 1995) and HAART in our cohort has been 
accompanied by substantial reductions in mortality caused by Pneumocystis pneumonia 
(Gona et al., 2006; Kaplan et al., 2000), which have continued to occur in post-HAART era 
only in infants born to women with late HIV-1 diagnosis or unmonitored pregnancy, 
causing failure to implement Pneumocystis pneumonia prophylaxis (Gibb et al., 2003; 
Simpson et al., 2000). The cases of M. avium complex infection in our cohort have decreased 
over time (Gona et al., 2006). The cases reported in CP2 were diagnosed in children 6-11 
years old, probably as a complication of advanced immunologic deterioration and the 
difficulty to realize a complete adherence to HAART and M. avium complex 
chemoprophylaxis. On the other hand, our data have shown an increase in the median age 
at death over time that might reflect improved management and prolongation in the time to 
development of a first bacteremia (Kapogiannis et al., 2008). More prolonged survival might 
allow chronic underlying comorbid conditions to become more clinically relevant in the next 
future. The proportion of HIV–related causes of deaths (12%) increased over time even if not 
statistically significant. Interestingly, the case of lactic acidosis was related to HAART 
regimen (stavudine + didanosine + efavirenz) that caused mitochondrial toxicity, whose rate 
is known to be increased by stavudine + didanosine co-administration (Blanco et al., 2003; 
Cote et al., 2002). Among non-HIV–related causes of death, the 7% of all the underlying 
causes, the fulminant hepatic failure occurred in 2008 was HCV-associated. We did not 
observe the increase of conditions, including diabetes mellitus, cancer, cardiovascular, liver 
and renal diseases that have become frequent in HIV-1–infected adults (Crum et al., 2006; 
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Lewden et al., 2008; Novoa et al., 2008; Palella et al., 2006; Sackoff et al., 2006; Smit et al., 
2006). The lack of increase of non-HIV–related causes of death might be due to the long 
duration pathogenesis of these diseases as well as to their rarity, which might have limited 
power to identify such evolution. 
The duration of initial HAART regimens for antiretroviral-naïve children has not been 
reported. On the contrary, several studies have assessed this public health issue in HIV-1–
infected adults (Chen et al., 2003; Miller et al., 1999; Palella Jr et al., 2002; Phillips et al., 
2001). The median duration of the first regimen observed in our study population was more 
than 3 years, the double of the duration described by Cheng and colleagues (2003) in a 
group of 405 antiretroviral-naïve adults and longer than that observed by Palella et al. (2002) 
who enrolled patients with previous antiretroviral experience. Notably, our study had a 
longer follow-up which could in part explain this difference. Among the therapy-naïve 
paediatric patients enrolled in the HIV Paediatric Cohort of the Comunidad Autónoma de 
Madrid, poor adherence has been identified as primary risk factor for initial HAART 
regimens discontinuation and short duration. This result is in agreement with the 
association between adherence and response to antiretroviral therapy reported for 
paediatric patients, being incomplete adherence the primary cause of treatment failure 
(Chiappini et al., 2006; Gray et al., 2001; Hainaut et al., 2003; Resino et al., 2003). In 
addiction, the age at HAART initiation was found to be another independent risk factor for 
first HAART regimen discontinuation. The impact of HAART on the morbidity and 
mortality in Spanish HIV-1 vertically infected children has been discussed elsewhere 
(Resino et al., 2006b; Sanchez et al., 2003). However, an assessment of underlying causes of 
mortality and a population effectiveness analysis have never been performed in the context 
of an observational paediatric cohort in Spain. A number of limitations of this study should 
be noted. First, temporal changes in the spectrum of causes of deaths were not statistically 
significant; whether this result has been due to the limited number of deaths occurred after 
1996 should be cautiously taken into account. Second, a survivor bias due to the partially 
retrospective enrolment might have caused mortality underestimation in infants at the 
beginning of the epidemic. Nevertheless our cohort remains more than representative of the 
HIV-1 epidemic in one of the Spanish regions most affected by the disease over almost three 
decades.  
5. Conclusion 
Despite the population effectiveness of HAART in reducing HIV-1-associated mortality, 
new challenges could arise for national surveillance systems as prolonged survival and 
long-term antiretroviral exposure might contribute to additional and different causes of 
death in perinatally infected patients in the future. 
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